

Giorgia Giussani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8358967/publications.pdf>

Version: 2024-02-01

74
papers

66,329
citations

81743

39
h-index

79541

73
g-index

77
all docs

77
docs citations

77
times ranked

92476
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. <i>Journal of Neurology</i> , 2022, 269, 2080-2098.	1.8	21
2	Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. <i>Journal of Neurology</i> , 2022, 269, 2265-2274.	1.8	39
3	Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment. <i>Epilepsia</i> , 2022, 63, 335-351.	2.6	12
4	Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study. <i>Neurological Sciences</i> , 2022, 43, 5133-5141.	0.9	6
5	Burden of Neurological Disorders Across the US From 1990-2017. <i>JAMA Neurology</i> , 2021, 78, 165.	4.5	262
6	The management of epilepsy in clinical practice: Do the timing and severity of the disease influence the priorities of patients and the caring physicians? Data from the EPINEEDS study. <i>Epilepsy and Behavior</i> , 2021, 114, 107201.	0.9	3
7	Discontinuation of antiseizure medications in seizure-free patients with long-term follow-up: Patients' profile, seizure recurrence, and risk factors. <i>Epilepsy and Behavior</i> , 2021, 117, 107871.	0.9	9
8	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. <i>The Cochrane Library</i> , 2021, 2021, CD007144.	1.5	3
9	Comorbidities in patients with epilepsy: Frequency, mechanisms and effects on long-term outcome. <i>Epilepsia</i> , 2021, 62, 2395-2404.	2.6	22
10	The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study. <i>Epilepsy and Behavior</i> , 2020, 102, 106641.	0.9	10
11	History of violence/maltreatment and psychogenic non-epileptic seizures. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 81, 8-12.	0.9	7
12	Risk factors for neonatal seizures: A case-control study in the province of Parma, Italy. <i>Epilepsy and Behavior</i> , 2020, 107, 107075.	0.9	2
13	Self-Report questionnaires for the diagnosis of psychogenic non-epileptic seizures in clinical practice. A comprehensive review of the available instruments. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 79, 30-43.	0.9	4
14	Prognostic patterns and predictors in epilepsy: a multicentre study (PRO-LONG). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1276-1285.	0.9	26
15	Generation and validation of algorithms to identify subjects with dementia using administrative data. <i>Neurological Sciences</i> , 2019, 40, 2155-2161.	0.9	1
16	Epidemiology and familial clustering of pediatric epilepsy in the geographic isolate of Ischia. <i>Epilepsy Research</i> , 2019, 154, 86-89.	0.8	2
17	Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 459-480.	4.9	2,625
18	Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 357-375.	4.9	526

#	ARTICLE	IF	CITATIONS
19	Italy's health performance, 1990â€“2017: findings from the Global Burden of Disease Study 2017. <i>Lancet Public Health</i> , The, 2019, 4, e645-e657.	4.7	54
20	Self-reporting versus clinical scrutiny: the value of adding questionnaires to the routine evaluation of seizure disorders. An exploratory study on the differential diagnosis between epilepsy and psychogenic nonepileptic seizures. <i>Epilepsy and Behavior</i> , 2019, 90, 191-196.	0.9	5
21	Treatment of epilepsy in light of the most recent advances. <i>Lancet Neurology</i> , The, 2019, 18, 7-8.	4.9	6
22	Italian Wikipedia and epilepsy: An infodemiological study of online information-seeking behavior. <i>Epilepsy and Behavior</i> , 2018, 81, 119-122.	0.9	8
23	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 118-125.	1.1	26
24	Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 63-77.	1.0	15
25	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1684-1735.	6.3	716
26	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	6.3	4,989
27	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1923-1994.	6.3	3,269
28	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1995-2051.	6.3	294
29	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	6.3	8,569
30	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 2091-2138.	6.3	335
31	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1859-1922.	6.3	2,123
32	Aging and the Epidemiology of Epilepsy. <i>Neuroepidemiology</i> , 2018, 51, 216-223.	1.1	101
33	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 391, 2236-2271.	6.3	638
34	Incidence of neonatal seizures, perinatal risk factors for epilepsy and mortality after neonatal seizures in the province of Parma, Italy. <i>Epilepsia</i> , 2018, 59, 1764-1773.	2.6	51
35	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2017, 390, 231-266.	6.3	480
36	Engaging psychiatrists in the diagnosis of psychogenic nonepileptic seizures. What can they contribute?. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 52, 182-187.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1084-1150.	6.3	573
38	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1260-1344.	6.3	1,589
39	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1151-1210.	6.3	3,565
40	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1211-1259.	6.3	5,578
41	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1345-1422.	6.3	1,879
42	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology</i> , The, 2017, 16, 877-897.	4.9	1,521
43	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1423-1459.	6.3	284
44	Long-term applicability of the new ILAE definition of epilepsy. Results from the PROLONG study. <i>Epilepsia</i> , 2017, 58, 1518-1523.	2.6	31
45	Patients and caregivers contributions for differentiating epileptic from psychogenic nonepileptic seizures. Value and limitations of self-reporting questionnaires: A pilot study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 53, 66-71.	0.9	15
46	Adult-Onset Epilepsy in Presymptomatic Alzheimer's Disease: A Retrospective Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1267-1274.	1.2	57
47	Antiepileptic drug discontinuation by people with epilepsy in the general population. <i>Epilepsia</i> , 2017, 58, 1524-1532.	2.6	19
48	In response: Towards a quantitative assessment of psychogenic nonepileptic seizures. <i>Epilepsia</i> , 2016, 57, 1011-1012.	2.6	0
49	Long-term prognosis of epilepsy, prognostic patterns and drug resistance: a population-based study. <i>European Journal of Neurology</i> , 2016, 23, 1218-1227.	1.7	24
50	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1603-1658.	6.3	1,612
51	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1459-1544.	6.3	4,934
52	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1545-1602.	6.3	5,298
53	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1659-1724.	6.3	4,203
54	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1813-1850.	6.3	413

#	ARTICLE	IF	CITATIONS
55	Peculiarities of Neurological Disorders and Study Designs. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 8-23.	3.0	1
56	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. <i>The Cochrane Library</i> , 2016, , CD007144.	1.5	20
57	The semiology of psychogenic nonepileptic seizures revisited: Can video alone predict the diagnosis? Preliminary data from a prospective feasibility study. <i>Epilepsia</i> , 2016, 57, 777-785.	2.6	57
58	Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. <i>Neurological Sciences</i> , 2016, 37, 579-583.	0.9	12
59	A population-based study of active and drug-resistant epilepsies in Northern Italy. <i>Epilepsy and Behavior</i> , 2016, 55, 30-37.	0.9	28
60	The natural history and prognosis of epilepsy. <i>Epileptic Disorders</i> , 2015, 17, 243-253.	0.7	152
61	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	6.3	4,951
62	Coffee and Amyotrophic Lateral Sclerosis. , 2015, , 429-434.		0
63	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
64	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	6.3	2,184
65	Prevalence and Incidence of Epilepsy in Italy Based on a Nationwide Database. <i>Neuroepidemiology</i> , 2014, 43, 228-232.	1.1	34
66	Prevalence and incidence of epilepsy in a wellâ€“defined population of Northern Italy. <i>Epilepsia</i> , 2014, 55, 1526-1533.	2.6	28
67	Physical activity and amyotrophic lateral sclerosis: A European populationâ€“based caseâ€“control study. <i>Annals of Neurology</i> , 2014, 75, 708-716.	2.8	79
68	Withdrawal of antiepileptic drugs: Guidelines of the Italian League Against Epilepsy. <i>Epilepsia</i> , 2013, 54, 2-12.	2.6	112
69	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 397-405.	1.1	68
70	Validation of healthcare administrative data for the diagnosis of epilepsy. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, 1019-1024.	2.0	41
71	Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 426-435.	0.8	13
72	Satisfaction with antiepileptic drugs in children and adolescents with newly diagnosed and chronic epilepsy. <i>Epilepsy Research</i> , 2012, 100, 142-151.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Trauma and amyotrophic lateral sclerosis: a case-control study from a population-based registry. European Journal of Neurology, 2012, 19, 1509-1517.	1.7	63
74	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	1.6	50